Clinical Trial Update: Real World Evidence of the Efficacy and Safety of FOQUEST [Phase 4]

View source ↗

Summary

Phase 4 real-world evidence trial evaluating efficacy and safety of FOQUEST in attention deficit-hyperactivity disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• FOQUEST

Snippet

Sponsor: Purdue Pharma, Canada | Conditions: Attention Deficit-Hyperactivity Disorder | Phase 4 | Status: COMPLETED